Krystal Biotech (NASDAQ:KRYS) Rating Increased to Strong-Buy at Zacks Research

Krystal Biotech (NASDAQ:KRYS) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

KRYS has been the subject of several other research reports. Guggenheim set a $224.00 price target on Krystal Biotech and gave the stock a “buy” rating in a research note on Friday, October 17th. Weiss Ratings restated a “hold (c+)” rating on shares of Krystal Biotech in a report on Monday, December 29th. Chardan Capital lifted their target price on shares of Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. HC Wainwright reiterated a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a research report on Monday, September 15th. Finally, Bank of America lifted their price objective on Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $228.14.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $248.91 on Wednesday. The firm has a market capitalization of $7.22 billion, a price-to-earnings ratio of 37.32 and a beta of 0.46. The business’s 50 day simple moving average is $226.28 and its 200-day simple moving average is $181.50. Krystal Biotech has a 12 month low of $122.80 and a 12 month high of $265.92.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $1.54. The firm had revenue of $97.80 million during the quarter, compared to analysts’ expectations of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. On average, equities analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current year.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the transaction, the insider owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. The trade was a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 13.70% of the stock is currently owned by company insiders.

Institutional Trading of Krystal Biotech

Several hedge funds and other institutional investors have recently bought and sold shares of KRYS. Hantz Financial Services Inc. lifted its stake in shares of Krystal Biotech by 8,950.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock worth $25,000 after purchasing an additional 179 shares during the period. Bessemer Group Inc. increased its stake in Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after purchasing an additional 77 shares during the last quarter. AdvisorNet Financial Inc purchased a new position in Krystal Biotech during the third quarter worth about $30,000. Salomon & Ludwin LLC purchased a new position in Krystal Biotech during the third quarter worth about $33,000. Finally, First Horizon Advisors Inc. boosted its stake in Krystal Biotech by 212.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock worth $34,000 after buying an additional 166 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.